IRLAB Therapeutics AB (publ) (STO:IRLAB.A)
Sweden
· Delayed Price · Currency is SEK 1.600
-0.016 (-0.99%)
At close: Mar 6, 2026
IRLAB Therapeutics AB Income Statement
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Operating Revenue | 57.46 | 94.63 | 5.68 | 61.14 | 207.78 | Upgrade
|
| Revenue | 57.46 | 94.63 | 5.68 | 61.14 | 207.78 | Upgrade
|
| Revenue Growth (YoY) | -39.28% | 1566.57% | -90.71% | -70.58% | 69160.67% | Upgrade
|
| Cost of Revenue | 99.38 | 136.29 | 128.41 | 125.91 | 81.74 | Upgrade
|
| Gross Profit | -41.91 | -41.66 | -122.73 | -64.77 | 126.05 | Upgrade
|
| Selling, General & Admin | 46.12 | 46.18 | 53.08 | 42.48 | 31.02 | Upgrade
|
| Other Operating Expenses | 1.05 | -19.46 | -0.04 | -0.03 | 38.97 | Upgrade
|
| Operating Expenses | 51.48 | 31.31 | 57.36 | 47.23 | 73.47 | Upgrade
|
| Operating Income | -93.4 | -72.97 | -180.09 | -112 | 52.58 | Upgrade
|
| Interest Expense | -17.99 | -10.48 | -0.2 | -0.3 | -0.37 | Upgrade
|
| Interest & Investment Income | 1.38 | 2.46 | 3.13 | - | 0 | Upgrade
|
| Currency Exchange Gain (Loss) | - | -2.14 | -0.68 | -1.11 | -0.43 | Upgrade
|
| Other Non Operating Income (Expenses) | -0 | - | 0 | - | - | Upgrade
|
| EBT Excluding Unusual Items | -110.01 | -83.13 | -177.84 | -113.41 | 51.78 | Upgrade
|
| Pretax Income | -110.01 | -83.13 | -177.84 | -113.41 | 51.78 | Upgrade
|
| Earnings From Continuing Operations | -110.01 | -83.13 | -177.84 | -113.41 | 51.78 | Upgrade
|
| Net Income | -110.01 | -83.13 | -177.84 | -113.41 | 51.78 | Upgrade
|
| Net Income to Common | -110.01 | -83.13 | -177.84 | -113.41 | 51.78 | Upgrade
|
| Shares Outstanding (Basic) | 67 | 52 | 52 | 52 | 52 | Upgrade
|
| Shares Outstanding (Diluted) | 67 | 52 | 52 | 52 | 52 | Upgrade
|
| Shares Change (YoY) | 29.17% | - | 0.07% | 0.16% | 8.54% | Upgrade
|
| EPS (Basic) | -1.64 | -1.60 | -3.43 | -2.19 | 1.00 | Upgrade
|
| EPS (Diluted) | -1.64 | -1.60 | -3.43 | -2.19 | 1.00 | Upgrade
|
| Free Cash Flow | -55.22 | -65.79 | -165.14 | -145.49 | 127.93 | Upgrade
|
| Free Cash Flow Per Share | -0.82 | -1.27 | -3.18 | -2.81 | 2.47 | Upgrade
|
| Gross Margin | -72.94% | -44.03% | - | -105.94% | 60.66% | Upgrade
|
| Operating Margin | -162.54% | -77.11% | -3171.72% | -183.20% | 25.30% | Upgrade
|
| Profit Margin | -191.45% | -87.85% | -3132.07% | -185.50% | 24.92% | Upgrade
|
| Free Cash Flow Margin | -96.10% | -69.52% | -2908.47% | -237.97% | 61.57% | Upgrade
|
| EBITDA | -89.08 | -72.08 | -179.17 | -111.27 | 53.07 | Upgrade
|
| EBITDA Margin | -155.02% | -76.17% | - | -182.00% | 25.54% | Upgrade
|
| D&A For EBITDA | 4.32 | 0.89 | 0.92 | 0.74 | 0.49 | Upgrade
|
| EBIT | -93.4 | -72.97 | -180.09 | -112 | 52.58 | Upgrade
|
| EBIT Margin | -162.54% | -77.11% | - | -183.20% | 25.30% | Upgrade
|
| Revenue as Reported | 62.8 | 114.08 | 5.72 | 61.28 | 207.91 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.